Lobbying

Revance Therapeutics's latest lobbying report covers Q2 2024, at $20K. Its first report covers Q4 2022; the issues it reports most are Health Issues.

Revance Therapeutics

Latest quarter
No record
Q2 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q2 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Revance Therapeutics lobbying by quarter
Revance Therapeutics lobbying by quarter
QuarterAmountReports
Q4 2022$20K1
Q1 2023$20K1
Q2 2023$20K1
Q3 2023$20K1
Q4 2023$20K1
Q1 2024$20K1
Q2 2024$20K1
Q3 2024$00
Q4 2024$00
Q1 2025$00
Q2 2025$00
Q3 2025$00
Q4 2025$00
Q1 2026$00
Q2 2026$00

Policy issues the reports name

  • Health issues7 reports

A report that names several issues counts once for each.

Who was lobbied

  • HOUSE OF REPRESENTATIVES7 reports
  • SENATE7 reports

Firms it paid

Firm
Jeffrey J. Kimbell & Associates$140K7 quarters

Former officials lobbying for it

Former position
JOHN HERZOGHealth Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the PresidentQ2 2024
JOHN R RAYLegislative Assistant, Rep. Mike KellyQ2 2024
KEITH STUDDARDLegislative Director, Rep. Marsha BlackburnQ2 2024
KELSEY CARLSONSpecial Assistant, National Security Council; Special Assistant, International Trade Administration, Dept of Commerce; Policy Advisor, Office of the Deputy Chief of Staff, Executive Office of the President; Confidential Assistant, Dept of CommerceQ2 2024

Lobbying reports

Filed by
24/07/19for Q2 2024Jeffrey J. Kimbell & Associates$20K
24/04/17for Q1 2024Jeffrey J. Kimbell & Associates$20K
24/01/18for Q4 2023Jeffrey J. Kimbell & Associates$20K
23/10/20for Q3 2023Jeffrey J. Kimbell & Associates$20K
23/07/20for Q2 2023Jeffrey J. Kimbell & Associates$20K
23/04/17for Q1 2023Jeffrey J. Kimbell & Associates$20K
23/01/18for Q4 2022Jeffrey J. Kimbell & Associates$20K